Skip to main content

Program News

November 18, 2020

New drug for metastatic colorectal cancer enters phase 3 trial

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.
February 4, 2021

Potential biomarker for IBD severity, cancer risk identified

A selenium transport protein produced in the colon is underexpressed in patients with ulcerative colitis and helps protect against colitis-associated cancer in an animal model, Vanderbilt investigators have discovered.
September 9, 2019

Bailey to direct general surgery residency program

Christina Bailey, MD, MSCI, assistant professor of Surgery, has been named the new program director of the general surgery residency training program in the Department of Surgery, Section of Surgical Sciences.

Singer’s concert honors care received at Cancer Center

Submitted by vicc_migrate on
A cancer patient’s gratitude toward his Vanderbilt-Ingram Cancer Center (VICC) physician led to a star-studded concert to benefit the Cancer Center. Colon cancer survivor and country artist Wade Hayes was joined by six-time CMA and ACM Female Vocalist of the Year Miranda Lambert, four-time Grammy and CMA Award-winning artist Steve Wariner and Kix Brooks, CMA […]

Study takes 3-D perspective on colorectal cancer

Submitted by vicc_migrate on
Despite dramatic recent advances in treatment, colorectal cancer killed more than 49,000 Americans last year, according to the National Cancer Institute, making it the second most lethal malignancy after cancers of the lung and bronchus. Determined to reduce the death toll, researchers at Vanderbilt University Medical Center recently put on their 3-D “glasses” and took […]

Researchers find novel mechanism of resistance to anti-cancer drugs

Submitted by vicc_migrate on
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors with genetic mutations that make them resistant to these anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, or the cancers develop resistance during treatment.
Subscribe to Gastrointestinal_Cancer_Research_Program